Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.66 |
| ▸ | RXRA | P19793 | 1/20 | 0.59 |
| ▸ | RXRB | P28702 | 1/20 | 0.59 |
| ▸ | RXRG | P48443 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 5/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253638 | 0.84 | IDO1 (0.45) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL11959143 | 0.84 | MAOB (0.72) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL1283338 | 0.83 | TAAR1 (0.47) | MAOBRXRARXRBRXRGCYP3A4 | |
| SCHEMBL693377 | 0.83 | RXRA (0.59) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL919538 | 0.82 | MAOB (0.56) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL3624161 | 0.81 | MAOB (0.73) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL7292908 | 0.80 | MAOB (0.67) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL921872 | 0.80 | MAOB (0.54) | MAOBRXRARXRBRXRGMAOA | |
| Methyl Alcohol SCHEMBL9626623 | 0.79 | RXRA (0.68) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL863891 | 0.79 | MAOB (0.66) | MAOBMAOANR4A2IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741887-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-03 | — | — | US | claimed |
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-05-16 | — | — | US | claimed |
| US-8367653-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | claimed |
| US-8362000-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | claimed |
| EP-2421847-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| EP-2421851-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | claimed |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| WO-2010124102-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| CN-101384256-A | PAI-1 Inhibitors for the Treatment of Muscle Conditions | WYETH CORP (US) | 2009-03-11 | — | — | CN | claimed |
| CN-1723198-A | Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH CORP (US) | 2006-01-18 | — | — | CN | claimed |
| WO-2016026830-A1 | NOVEL FUNGICIDAL PYRAZOLE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | WO | disclosed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8741887-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-03 | — | — | US | disclosed |
| US-4745120-A | CARDIOYASCULAR DISORDERS, ANTICOAGULANTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-05-17 | — | — | US | disclosed |
| US-4665080-A | THROMBOXANE SYNTHETASE INHIBITORS | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-05-12 | — | — | US | disclosed |
| EP-0173172-A2 | 3-Pyridyl compounds and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-03-05 | — | — | EP | disclosed |
| EP-0169408-A1 | Imidazolyl compounds, process for their preparation and their use as drugs | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MAOB 428/4885RXRA 1589/4885RXRB 1966/4885 |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MAOB 428/4885RXRA 1589/4885RXRB 1966/4885 |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | EGLN3, EGLN2, P4HA1 | MAOB 390/4885RXRA 2988/4885RXRB 2944/4885 |
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MAOB 428/4885RXRA 1589/4885RXRB 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.